Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Avidity Biosciences, Inc. (RNA) had Consolidated Net Income/Loss of $-115.77M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$1.57M |
|
$-115.77M |
|
-- |
|
$1.57M |
|
$133.09M |
|
$-131.52M |
|
$15.74M |
|
$-115.77M |
|
$-115.77M |
|
$-115.77M |
|
$-115.77M |
|
|
Consolidated Net Income/Loss |
$-115.77M |
$-115.77M |
|
$-131.52M |
|
$-135.89M |
|
129.23M |
|
129.23M |
|
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$1.43B |
|
$15.64M |
|
$24.10M |
|
$1.46B |
|
$84.86M |
|
-- |
|
$45.49M |
|
$130.35M |
|
$1.33B |
|
$1.33B |
|
$1.33B |
|
120.51M |
|
| Cash Flow Statement Financials | |
$-124.83M |
|
$157.19M |
|
$1.94M |
|
$222.66M |
|
$257.00M |
|
$34.34M |
|
$17.74M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-8360.90% |
|
-8360.90% |
|
-- |
|
-7360.01% |
|
-7360.01% |
|
$-128.58M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-8.71% |
|
-8.71% |
|
-7.93% |
|
-8.71% |
|
$11.03 |
|
$-0.99 |
|
$-0.97 |
|